The largest database of trusted experimental protocols

Alteplase actilyse

Manufactured by Boehringer Ingelheim
Sourced in Germany

Alteplase (Actilyse®) is a recombinant tissue-type plasminogen activator (rt-PA) used as a thrombolytic agent. It is designed to dissolve blood clots in patients experiencing acute ischemic stroke, acute myocardial infarction, or acute massive pulmonary embolism.

Automatically generated - may contain errors

3 protocols using alteplase actilyse

1

Thrombin Inhibition Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human α-thrombin was obtained from CellSystems (St. Katharinen, Germany). Argatroban (Argatra®) was obtained from Mitsubishi Pharma (Düsseldorf, Germany). The 3’-biotinylated DNA-aptamer HD1-22 was synthesized and purified from Microsynth (Balgach, Switzerland). The fluorogenic peptide substrate I-1560 (Thrombin, Boc-Asp(OBzl)-Pro-Arg-AMC) was purchased from Bachem (Weil am Rhein, Germany). Alteplase (Actilyse®) was purchased from Boehringer Ingelheim (Biberach, Germany).
+ Open protocol
+ Expand
2

Preparation and Dosing of Apixaban and Alteplase

Check if the same lab product or an alternative is used in the 5 most similar protocols
Apixaban (provided by Pfizer Inc., United States; material no. 1151519, batch no. ABA8622) was initially dissolved in dimethyl sulfoxide, and subsequently diluted with PBS to a concentration of 2.5 mg ml−1. Diluted Apixaban was stored aliquoted at −20°C and was not re-frozen once thawed. Concentration of Apixaban was selected to be in line with clinically relevant dosing for the secondary prevention of thrombotic events in patients with atrial fibrillation, which is 250 ng ml−1 (Artang et al., 2017 (link)).
Alteplase (Actilyse, provided by Boehringer-Ingelheim International GmbH, Germany; Z. Nr. 1-24,717) was dissolved in distilled water to a concentration of 1 mg ml−1 and was stored aliquoted at -20°C (not re-frozen once thawed); after which it was further diluted with PBS. The final concentration of alteplase was also selected to be in line with clinically relevant dosing indicated for patients with ischemic stroke (1.3 mg L−1), according to the manufacturer’s instructions and supporting pharmacokinetic data (Acheampong and Ford, 2012 (link)).
+ Open protocol
+ Expand
3

Clot Formation Assay with Fibrinogen Supplements

Check if the same lab product or an alternative is used in the 5 most similar protocols
Clots were formed from 30% PNP or FDP supplemented with cryoprecipitate, RiaSTAP® (CSL Behring GmbH, Marburg, Germany) or FibCLOT® (LFB, Les Ulis, France) (0.5–2 mg/mL) in the presence of 16 mM phospholipids (Rossix, Mölndal, Sweden) ± 300 pM tPA (Alteplase (Actilyse®) Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany) in Tris buffered saline with Tween-20 (TBST; 10 mM Tris, 140 mM NaCl and 0.01% Tween-20 pH 7.4). Clotting was initiated with CaCl2 (10.6 mM) and thrombin (0.1 U/mL, Sigma Aldrich Sigma-Aldrich, Darmstadt, Germany), and absorbance readings were taken every min for 4 h at 37 °C in a in a FLX-800 plate reader (Biotek Instruments, Winooski, VT, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!